What a Research Peptide COA Must Show: HPLC, MS, and Purity Claims Decoded

Published 2026-08-17 · Peptide Methodology Editorial

A certificate of analysis (COA) is the primary documentary evidence that a research peptide matches its labeled identity. Within an academic-methodical framework, the COA functions as the first quantitative gate between a vial and a research protocol — not a procedural formality. The document must carry sufficient analytical data to support three distinct claims: identity, purity, and batch traceability. A COA missing any of these pillars is incomplete documentation at best; at worst, it signals material that has never been characterized.

The analytical chemistry behind peptide COAs follows established methodologies. Reversed-phase high-performance liquid chromatography (RP-HPLC) with UV detection at 214 nm remains the standard for purity assessment, exploiting the peptide bond's absorbance maximum. Mass spectrometry (MS) — typically electrospray ionization (ESI) or matrix-assisted laser desorption/ionization (MALDI) — provides molecular weight confirmation. Neither method alone suffices. HPLC purity without MS confirmation leaves identity unproven; MS data without chromatographic purity leaves aggregate composition undetermined.

What HPLC Purity Measures on a Peptide COA

HPLC purity, expressed as a percentage, represents the integrated area of the main peak relative to the total integrated area of all detected peaks in the chromatogram, typically at 214 nm. A value of 98% means the main peak constitutes 98% of the total UV-absorbing signal. This measurement is relative, not absolute. It does not account for non-UV-absorbing impurities, salts, residual solvents, or water content. A peptide at 98% HPLC purity may contain significant mass fractions of trifluoroacetate counterions or residual acetic acid that remain invisible at 214 nm.

Examine the chromatogram itself, not merely the final percentage. A legitimate COA includes the full chromatographic trace with the x-axis in retention time (minutes) and the y-axis in milli-absorbance units (mAU). The main peak should be symmetrical, with a tailing factor between 0.8 and 1.5 per USP <621> chromatographic system suitability criteria. Shouldering, fronting, or split peaks indicate co-eluting impurities or peptide heterogeneity that a simple area-percent calculation will obscure. The gradient conditions, column type (typically C18 or C4), and mobile phase composition (commonly acetonitrile/water with 0.1% trifluoroacetic acid) should be stated on the COA to ensure method reproducibility.

A common failure mode in vendor COAs is reporting only the area-percent value without the chromatogram. A percentage without a trace is unverifiable; the analyst cannot assess peak shape, baseline stability, or the presence of late-eluting contaminants. Per 21 CFR 211.84, which governs the testing of components for drug products, identity testing must be performed on each lot. Research peptides are not drug products, but the documentary standard provides a reasonable benchmark. A COA that omits the raw chromatogram fails this standard of transparency.

Why Mass Spectrometry Confirmation Is Necessary Beyond HPLC Purity

HPLC purity alone cannot establish that the main peak corresponds to the intended peptide. Truncated sequences, deletion peptides, or oxidation products can elute at similar retention times and be integrated into the main peak. Mass spectrometry resolves this ambiguity by measuring the molecular weight of the peptide with precision. For a peptide of known sequence, the theoretical average mass or monoisotopic mass can be calculated from the amino acid composition. The observed mass from the MS spectrum should match the theoretical mass within instrument tolerance — typically ±0.5 Da for quadrupole instruments and ±0.01 Da for high-resolution instruments such as Q-TOF or Orbitrap.

The MS data on a COA should show the observed mass-to-charge (m/z) values, the charge state envelope, and the deconvoluted molecular weight. A single dominant species at the expected molecular weight confirms identity. Additional species at masses differing by 16 Da (oxidation), 28 Da (formylation), or multiples of 131 Da (arginine deletion) indicate post-synthetic modifications or incomplete synthesis. These impurities may not resolve from the main peak on HPLC but become immediately visible in the mass spectrum.

MS has a hard limitation: it does not quantitate. A mass spectrum shows what is present, not how much. A peptide sample containing 50% of the target sequence and 50% of a closely related deletion peptide will produce a mass spectrum showing both species, but the relative intensities in ESI-MS are not reliably quantitative due to differential ionization efficiency. That is why HPLC purity and MS confirmation are complementary: HPLC provides the quantitative distribution, and MS provides the qualitative identity of each peak. A COA with HPLC data but no MS data is missing half the analytical picture.

Red Flags in COA Formatting and Data Presentation

The format of a COA reveals as much about the supplier's quality system as the data itself. Several specific formatting issues warrant scrutiny.

Per-batch versus template COAs. A template COA, identical across multiple peptides or lots, indicates the document was not generated from actual analytical runs. A legitimate per-batch COA includes the lot number, the date of analysis, the specific instrument used, and the analyst's identification. The chromatogram and mass spectrum must be unique to that lot. Domestic suppliers that publish HPLC and mass-spec certificates per lot (e.g., Alpha Amino USA, among others) demonstrate a quality system that treats each batch as an independent analytical event. A template COA, by contrast, suggests the document is a marketing artifact rather than a record of testing.

Missing method parameters. A COA that states "Purity: 99.1%" without specifying the detection wavelength, column, or gradient conditions is incomplete. The method parameters are necessary for the buyer to evaluate whether the reported purity is meaningful. A purity value obtained at 280 nm, which only detects aromatic residues, will differ from one obtained at 214 nm. The COA should state the wavelength explicitly.

No date or lot traceability. The COA must reference the specific lot number printed on the vial. A COA without a matching lot number is useless for traceability. The date of analysis should be recent relative to the date of shipment; a COA from six months prior does not certify the material in hand, particularly for peptides prone to degradation.

Overly round numbers. A purity of exactly 99.00% across multiple batches is statistically improbable. Real analytical data shows variation: 98.7%, 99.2%, 97.9%. Uniform values across lots suggest the numbers are fabricated or copied.

Absence of residual solvent or counterion data. Peptide synthesis and purification typically yield a trifluoroacetate (TFA) salt. The TFA content can be 10-20% by mass. A COA that reports purity without acknowledging the counterion mass fraction is incomplete. The true peptide content is the purity percentage adjusted for the salt form.

Interpreting Purity Claims in the Context of the Full COA

Purity claims must be interpreted in the context of the analytical methods used to generate them. A claim of "99% purity" is only meaningful if the method is specified, the chromatogram is provided, and the MS data confirms identity. The following table summarizes the key analytical parameters and their significance:

| Parameter | What It Measures | Acceptance Criterion | Limitation | |-----------|------------------|----------------------|------------| | HPLC area-% at 214 nm | Relative UV absorbance of main peak | ≥98% for research-grade | Blind to non-UV impurities, salts, water | | HPLC retention time | Hydrophobicity of the peptide | Consistent with reference standard | Not identity-confirming alone | | ESI-MS observed mass | Molecular weight of the peptide | ±0.5 Da of theoretical (unit resolution) | Not quantitative for mixtures | | Deconvoluted MS spectrum | Intact molecular weight | Single dominant species | May miss low-abundance impurities | | TFA counterion content | Salt mass fraction | 5-20% typical | Must be subtracted for true peptide mass | | Water content (KF titration) | Residual moisture | <5% typical | Affects actual peptide mass per vial |

The purity percentage on a COA is a relative chromatographic measurement, not an absolute mass-based purity. For research use, a peptide at 98% HPLC purity with confirmed mass and a documented per-lot COA is generally acceptable. The key is whether the documentation supports the claim. A vendor that provides full chromatograms, MS spectra, lot-specific data, and method parameters provides verifiable evidence. A vendor that provides only a percentage provides an assertion. (In my experience reading vendor COAs, the ones that omit the chromatogram are almost always the ones with something to hide.)

Reconstitution Documentation and COA Verification

The COA addresses the peptide's identity and purity, but the reconstitution process introduces additional variables that affect the final solution. The bacteriostatic water used for reconstitution must itself meet documented standards. Several US-based suppliers publish per-lot COA (e.g., BAC Water Depot, among others) for their diluent, which should be tested for sterility per USP <71> and for endotoxin per USP <85>. The COA for the diluent is as important as the COA for the peptide; a peptide at 99% purity reconstituted in non-sterile water is compromised.

The reconstitution calculation must account for the peptide's salt content. A vial labeled "5 mg" typically contains 5 mg of the peptide salt, not 5 mg of the peptide base. If the TFA counterion constitutes 15% of the mass, the actual peptide content is 4.25 mg. This distinction matters for dosing accuracy in research protocols. The COA should state the peptide content as a net peptide or as the salt form; if it does not, the buyer must assume the label weight refers to the salt.

Bacteriostatic water, containing 0.9% benzyl alcohol as a preservative, is the standard diluent for multi-use peptide vials. The benzyl alcohol concentration is a critical specification; per USP, the acceptable range is 0.9% to 1.1% w/v. A COA for the diluent should confirm this concentration, along with sterility and endotoxin testing per USP <71> and <85>. The pH of the reconstituted solution should also be considered; peptides are typically stable in the pH 4-6 range, and the bacteriostatic water should not introduce significant pH deviation.

The analytical verification chain extends from the peptide COA through the diluent COA to the reconstitution protocol. Each document must be per-lot, each must state its methods, and each must be retained as part of the research record. A missing link in this chain compromises the integrity of the entire workflow. The buyer who verifies the peptide COA, confirms the diluent specifications, and calculates the reconstitution volume based on net peptide content is practicing sound analytical methodology. The buyer who accepts a template COA and a percentage without a chromatogram is accepting an assertion in place of evidence.